Clinical Trial Update: CART-meso in Mesothelin Expressing Cancers [Phase 1]

View source ↗

Summary

Phase 1 update on CART-meso, a mesothelin-targeted CAR T-cell therapy, tested in mesothelin-expressing cancers including metastatic pancreatic ductal adenocarci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Malignant Pleural Mesothelioma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CART-meso (mesothelin-targeted CAR T-cell therapy)

Snippet

Sponsor: University of Pennsylvania | Conditions: Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer | Phase 1 | Status: COMPLETED